$11 million grant for cancer survivorship
Volume 4, Issue 4, 2015
Study explores prognosis and quality of life in non-Hodgkin lymphoma patients.
James R. Cerhan, M.D., Ph.D.
The Mayo Clinic Cancer Center has received a five-year, $11 million grant from the National Cancer Institute (NCI) to study survivorship in patients with non-Hodgkin lymphoma (NHL).
The grant provides funding for the Lymphoma Epidemiology of Outcomes Cohort Study, which will enroll 12,000 patients with non-Hodgkin lymphoma. The study will follow these patients to learn more about long-term prognosis and survivorship issues.
"With an increasing number of Americans living with NHL, we need to find new and better ways to improve the length and quality of their lives," said the study's principal investigator, James R. Cerhan, M.D., Ph.D., an epidemiologist in the Mayo Clinic Cancer Center.
Non-Hodgkin lymphoma, also called non-Hodgkin's lymphoma, is a cancer that develops from lymphocytes, a type of white blood cell.
According to the NCI, nearly 72,000 cases of non-Hodgkin lymphoma will be diagnosed in the U.S. in 2015. Although incidence of non-Hodgkin lymphoma has been increasing since 1950, the rate of the increase has slowed during the past two decades, and survival rates have improved. These trends have led to an increasing number of survivors, most recently estimated at 550,000.
The NCI grant involves collaboration among multiple institutions, including lymphoma experts from the Mayo Clinic Cancer Center, the University of Iowa, Emory University/Grady Health System, MD Anderson Cancer Center, the University of Wisconsin, Cornell University, and the University of Miami Health System/Jackson Memorial Hospital.